4D Molecular Therapeutics, Inc. (FDMT) › Cash & Equivalents4D Molecular Therapeutics, Inc. (FDMT) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $49.65M2020: $276.73M2021: $153.00M2022: $52.35M2023: $249.11M2024: $149.34M2025: $60.24M$60.24M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$60.24M-59.7%2024$149.34M-40.1%2023$249.11M+375.8%2022$52.35M-65.8%2021$153.00M-44.7%2020$276.73M+457.3%2019$49.65M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share